SYFOVRE^® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

SELECT SAFETY INFORMATION
SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

Please see additional Important Safety Information below.

JOIN US for a Virtual Program

Objectives

In this interactive webinar, you will hear from an optometrist and a retinal specialist as they discuss diagnosing patients with geographic atrophy (GA). They will review the following topics as they pertain to the typical geographic atrophy patient:

• Risk factors associated with GA
• Common imaging modalities and techniques for accurate detection of GA
• Review of a potential treatment for GA

UPCOMING WEBINARS

Wednesday, November 13, 2024
9:30 PM ET – 10:30 PM ET

Presenters:

Jordana Fein, MD
Retina Group of Washington
Fairfax, VA

Julie Rodman, OD, MS, FAAO
Nova Southeastern University
Fort Lauderdale, FL

By registering for these event, you acknowledge that you have reviewed and agreed to our Terms of Use and Privacy Policy.

This educational event is presented by Apellis Pharmaceuticals, Inc. and all faculty are paid consultants of Apellis Pharmaceuticals, Inc. This program is intended for U.S eyecare professionals only. Guests and spouses may not attend this program. This is a promotional program and no CE/CME credits are offered.

INDICATION

SYFOVRE^® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 

• SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. 

• Retinal Vasculitis and/or Retinal Vascular Occlusion 

  • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay. 

• Neovascular AMD

  • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

• Intraocular Inflammation

  • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE. 

• Increased Intraocular Pressure

  • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

• Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full Prescribing Information for more information.